(Malignant Melanoma) Cobimetinib Plus Vemurafenib: coBRIM Phase 3 Trial Results
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- August 5, 2016
- 1 min read
On August 3, 2016, The Lancet Oncology published results demonstrating that the combination of cobimetinib and vemurafenib is effective as first-line treatment for BRAF V600 mutation-positive malignant melanoma.
Vemurafenib is a BRAF inhibitor used in malignant melanoma treatment. The coBRIM trial evaluated vemurafenib combined with cobimetinib (brand name Cotellic, a MAPK MEK inhibitor), confirming a median PFS of 12.3 months. With vemurafenib alone, median PFS was 7.2 months (p<0.0001).
At data analysis (August 28, 2015), 52% of patients had died. Median OS: cobimetinib combination 22.3 months vs. vemurafenib alone 17.4 months (p<0.005).
coBRIM Trial Design (NCT01689519):
The coBRIM trial began in January 2013 across 193 sites in the United States, Europe, Russia, and Israel. It enrolled 495 patients with BRAF V600 mutation-positive unresectable Stage 3c or Stage 4 malignant melanoma. Patients were randomized 1:1 to cobimetinib or placebo, both administered with vemurafenib. Treatment cycle was 28 days: cobimetinib 60 mg once daily for Days 1–21, then 7 days off; vemurafenib 960 mg for all 28 days. Primary endpoints were PFS and OS duration.
Conclusion: The coBRIM trial demonstrated that combination cobimetinib plus vemurafenib is effective for patients with BRAF V600 mutation-positive malignant melanoma.
Source: A Phase III Study Comparing Vemurafenib vs Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With Metastatic Melanoma (coBRIM)
Malignant Melanoma | BRAF V600 | MEK Inhibitor | Targeted Therapy
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4